BioCentury
ARTICLE | Clinical News

Arzerra ofatumumab regulatory update

July 20, 2015 7:00 AM UTC

Novartis submitted an application to EMA to expand the label of Arzerra ofatumumab to include maintenance treatment of relapsed chronic lymphocytic leukemia (CLL). The human mAb against CD20 is approv...